Research
Hormonal
The presence of anti-drug antibodies (ADAs) to GLP-1 receptor agonists does not necessarily neutralize their clinical efficacy, although it may increase the risk of hypersensitivity reactions.
If you develop antibodies to your GLP-1 medication, it does not automatically mean it has stopped working for weight loss. However, you may experience more injection site reactions. Discuss these symptoms with your doctor; they may not need to stop the drug unless side effects are severe.
GoodQualifiesHIGH confidence
Ultimately, it was shown that their presence affected neither the pharmacokinetics nor the efficacy of the drug. However, ADAs were associated with a higher incidence of hypersensitivity and injection site reactions compared to the group of patients who did not develop them.
Why this rating
Based on large-scale trial data (SURPASS studies) for tirzepatide and SUSTAIN studies for semaglutide.
Source
Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure
Michał Nicze et al. · International Journal of Molecular Sciences · 2026
DOI 10.3390/ijms27062539
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP1R gene polymorphisms (specifically rs10305420 and rs6923761) significantly predict differential weight loss responses to GLP-1 receptor agonists like liraglutide, with certain variants linked to poor anti-obesity response.Good
- Phenotype-guided treatment selection (matching drug mechanism to obesity subtype like 'hungry brain' or 'slow burn') results in significantly greater weight loss compared to standard care.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →